Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Molecular Diagnostics Lab, |
RCV000498830 | SCV000590873 | pathogenic | not provided | 2015-12-30 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV000549803 | SCV000638075 | pathogenic | Familial hypocalciuric hypercalcemia; Autosomal dominant hypocalcemia 1 | 2024-11-30 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 143 of the CASR protein (p.Gly143Glu). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with familial hypocalciuric hypercalcemia (FHH) (PMID: 1302026, 7726161, 26963950). It has also been observed to segregate with disease in related individuals. Invitae Evidence Modeling of clinical and family history, age, sex, and reported ancestry of multiple individuals with this CASR variant has been performed. This variant is expected to be pathogenic with a positive predictive value of at least 99%. This is a validated machine learning model that incorporates the clinical features of 606,512 individuals referred to our laboratory for CASR testing. This variant is also known as Gly144Glu. ClinVar contains an entry for this variant (Variation ID: 8333). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects CASR function (PMID: 8702647, 10077597, 12095982, 12114500, 12890593, 19389809, 23077345). This variant disrupts the p.Gly143 amino acid residue in CASR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 19179454, 32347971; internal data). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV002271366 | SCV002556052 | pathogenic | Familial hypocalciuric hypercalcemia | 2022-06-02 | criteria provided, single submitter | clinical testing | Variant summary: CASR c.428G>A (p.Gly143Glu) results in a non-conservative amino acid change located in the Receptor, ligand binding region of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251406 control chromosomes. c.428G>A has been reported in the literature in multiple individuals affected with Familial Hypocalciuric Hypercalcemia (examples: Chou_1992, Chou_1995, Vargas-Poussou_2016, etc). At least one publication reports the variant to lead to defective localization to plasma membrane compared to WT (White_2009). Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
| OMIM | RCV000008835 | SCV000029045 | pathogenic | Familial hypocalciuric hypercalcemia 1 | 1995-05-01 | no assertion criteria provided | literature only |